Many meta-analyses and trials, including the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced), Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved), and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), showed that SGLT2 inhibitors can decrease hospitalization for HF in both HFrEF and HFpEF patients regardless of diabetes status [355,356,357,358]. The gene discussed is SLC5A2; the disease is congestive heart failure.